Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2010

01-10-2010 | Preclinical study

Gene amplification in ductal carcinoma in situ of the breast

Authors: L. Burkhardt, T. J. Grob, I. Hermann, E. Burandt, M. Choschzick, F. Jänicke, V. Müller, C. Bokemeyer, R. Simon, G. Sauter, W. Wilczak, A. Lebeau

Published in: Breast Cancer Research and Treatment | Issue 3/2010

Login to get access

Abstract

Multiple different biologically and clinically relevant genes are often amplified in invasive breast cancer, including HER2, ESR1, CCND1, and MYC. So far, little is known about their role in tumor progression. To investigate their significance for tumor invasion, we compared pure ductal carcinoma in situ (DCIS) and DCIS associated with invasive cancer with regard to the amplification of these genes. Fluorescence in situ hybridization (FISH) was performed on a tissue microarray containing samples from 130 pure DCIS and 159 DCIS associated with invasive breast cancer. Of the latter patients, we analyzed the intraductal and invasive components separately. In addition, lymph node metastases of 23 patients with invasive carcinoma were included. Amplification rates of pure DCIS and DCIS associated with invasive cancer did not differ significantly (pure DCIS vs. DCIS associated with invasive cancer: HER2 22.7 vs. 24.2%, ESR1 19.0 vs. 24.1%, CCND1 10.0 vs. 14.8%, MYC 11.8 vs. 6.5%; P > 0.05). Furthermore, we observed a high concordance of the amplification status for all genes if in situ and invasive carcinoma of individual patients were compared. This applied also to the corresponding lymph node metastases. Our results indicate no significant differences between the gene amplification status of DCIS and invasive breast cancer concerning HER2, ESR1, CCND1, and MYC. Therefore, our data suggest an early role of all analyzed gene amplifications in breast cancer development but not in the initiation of invasive tumor growth.
Literature
1.
Kallioniemi OP, Kallioniemi A, Kurisu W, Thor A, Chen LC, Smith HS, Waldman FM, Pinkel D, Gray JW (1992) ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci USA 89:5321–5325CrossRefPubMed
2.
King CR, Kraus MH, Aaronson SA (1985) Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229:974–976CrossRefPubMed
3.
Berns EM, Klijn JG, van Staveren IL, Portengen H, Noordegraaf E, Foekens JA (1992) Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors. Eur J Cancer 28:697–700CrossRefPubMed
4.
Rummukainen JK, Salminen T, Lundin J, Kytola S, Joensuu H, Isola JJ (2001) Amplification of c-myc by fluorescence in situ hybridization in a population-based breast cancer tissue array. Mod Pathol 14:1030–1035CrossRefPubMed
5.
Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM, Meltzer PS (1997) AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277:965–968CrossRefPubMed
6.
Courjal F, Cuny M, Rodriguez C, Louason G, Speiser P, Katsaros D, Tanner MM, Zeillinger R, Theillet C (1996) DNA amplifications at 20q13 and MDM2 define distinct subsets of evolved breast and ovarian tumours. Br J Cancer 74:1984–1989PubMed
7.
Barlund M, Forozan F, Kononen J, Bubendorf L, Chen Y, Bittner ML et al (2000) Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. J Natl Cancer Inst 92:1252–1259CrossRefPubMed
8.
Luoh SW, Venkatesan N, Tripathi R (2004) Overexpression of the amplified Pip4k2beta gene from 17q11-12 in breast cancer cells confers proliferation advantage. Oncogene 23:1354–1363CrossRefPubMed
9.
Hui R, Campbell DH, Lee CS, McCaul K, Horsfall DJ, Musgrove EA, Daly RJ, Seshadri R, Sutherland RL (1997) EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in primary breast cancer. Oncogene 15:1617–1623CrossRefPubMed
10.
Bellacosa A, de Feo D, Godwin AK, Bell DW, Cheng JQ, Altomare DA et al (1995) Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 64:280–285CrossRefPubMed
11.
Jarvinen TA, Tanner M, Barlund M, Borg A, Isola J (1999) Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes Chromosomes Cancer 26:142–150CrossRefPubMed
12.
Bautista S, Theillet C (1998) CCND1 and FGFR1 coamplification results in the colocalization of 11q13 and 8p12 sequences in breast tumor nuclei. Genes Chromosomes Cancer 22:268–277CrossRefPubMed
13.
Ro J, North SM, Gallick GE, Hortobagyi GN, Gutterman JU, Blick M (1988) Amplified and overexpressed epidermal growth factor receptor gene in uncultured primary human breast carcinoma. Cancer Res 48:161–164PubMed
14.
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182CrossRefPubMed
15.
Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF (2009) Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 27:1323–1333CrossRefPubMed
16.
Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118–145CrossRefPubMed
17.
Holst F, Stahl PR, Ruiz C, Hellwinkel O, Jehan Z, Wendland M et al (2007) Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet 39:655–660CrossRefPubMed
18.
Brown LA, Hoog J, Chin SF, Tao Y, Zayed AA, Chin K et al (2008) ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet 40:806–807 (author reply 810–812)CrossRefPubMed
19.
Horlings HM, Bergamaschi A, Nordgard SH, Kim YH, Han W, Noh DY et al (2008) ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet 40:807–808 (author reply 810–812)CrossRefPubMed
20.
Reis-Filho JS, Drury S, Lambros MB, Marchio C, Johnson N, Natrajan R et al (2008) ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet 40:809–810 (author reply 810–812)CrossRefPubMed
21.
Vincent-Salomon A, Raynal V, Lucchesi C, Gruel N, Delattre O (2008) ESR1 gene amplification in breast cancer: a common phenomenon? Nat Genet 40:809 (author reply 810–812)CrossRefPubMed
22.
Adelaide J, Finetti P, Charafe-Jauffret E, Wicinski J, Jacquemier J, Sotiriou C, Bertucci F, Birnbaum D, Chaffanet M (2008) Absence of ESR1 amplification in a series of breast cancers. Int J Cancer 123:2970–2972CrossRefPubMed
23.
Tomita S, Zhang Z, Nakano M, Ibusuki M, Kawazoe T, Yamamoto Y, Iwase H (2009) Estrogen receptor alpha gene ESR1 amplification may predict endocrine therapy responsiveness in breast cancer patients. Cancer Sci 100:1012–1017CrossRefPubMed
24.
Bedard PL, Piccart-Gebhart MJ (2009) Progress in tailoring adjuvant endocrine therapy for postmenopausal women with early breast cancer. Curr Opin Oncol 21:491–498PubMed
25.
Borg A, Baldetorp B, Ferno M, Olsson H, Sigurdsson H (1992) c-myc Amplification is an independent prognostic factor in postmenopausal breast cancer. Int J Cancer 51:687–691CrossRefPubMed
26.
Champeme MH, Bieche I, Hacene K, Lidereau R (1994) Int-2/FGF3 amplification is a better independent predictor of relapse than c-myc and c-erbB-2/neu amplifications in primary human breast cancer. Mod Pathol 7:900–905PubMed
27.
Chen Y, Olopade OI (2008) MYC in breast tumor progression. Expert Rev Anticancer Ther 8:1689–1698CrossRefPubMed
28.
Persons DL, Borelli KA, Hsu PH (1997) Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization. Mod Pathol 10:720–727PubMed
29.
Deming SL, Nass SJ, Dickson RB, Trock BJ (2000) C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance. Br J Cancer 83:1688–1695CrossRefPubMed
30.
Naidu R, Wahab NA, Yadav M, Kutty MK (2002) Protein expression and molecular analysis of c-myc gene in primary breast carcinomas using immunohistochemistry and differential polymerase chain reaction. Int J Mol Med 9:189–196PubMed
31.
Berns EM, Klijn JG, van Putten WL, van Staveren IL, Portengen H, Foekens JA (1992) c-myc Amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. Cancer Res 52:1107–1113PubMed
32.
Scorilas A, Trangas T, Yotis J, Pateras C, Talieri M (1999) Determination of c-myc amplification and overexpression in breast cancer patients: evaluation of its prognostic value against c-erbB-2, cathepsin-D and clinicopathological characteristics using univariate and multivariate analysis. Br J Cancer 81:1385–1391CrossRefPubMed
33.
Schlotter CM, Vogt U, Bosse U, Mersch B, Wassmann K (2003) C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer. Breast Cancer Res 5:R30–R36CrossRefPubMed
34.
Seshadri R, Lee CS, Hui R, McCaul K, Horsfall DJ, Sutherland RL (1996) Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis. Clin Cancer Res 2:1177–1184PubMed
35.
Naidu R, Wahab NA, Yadav MM, Kutty MK (2002) Expression and amplification of cyclin D1 in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters. Oncol Rep 9:409–416PubMed
36.
Butt AJ, McNeil CM, Musgrove EA, Sutherland RL (2005) Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E. Endocr Relat Cancer 12(Suppl 1):S47–S59CrossRefPubMed
37.
Robanus-Maandag EC, Bosch CA, Kristel PM, Hart AA, Faneyte IF, Nederlof PM, Peterse JL, van de Vijver MJ (2003) Association of C-MYC amplification with progression from the in situ to the invasive stage in C-MYC-amplified breast carcinomas. J Pathol 201:75–82CrossRefPubMed
38.
Watson PH, Safneck JR, Le K, Dubik D, Shiu RP (1993) Relationship of c-myc amplification to progression of breast cancer from in situ to invasive tumor and lymph node metastasis. J Natl Cancer Inst 85:902–907CrossRefPubMed
39.
Lebeau A, Unholzer A, Amann G, Kronawitter M, Bauerfeind I, Sendelhofert A, Iff A, Lohrs U (2003) EGFR, HER-2/neu, cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast. Breast Cancer Res Treat 79:187–198CrossRefPubMed
40.
Bartkova J, Barnes DM, Millis RR, Gullick WJ (1990) Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ. Hum Pathol 21:1164–1167CrossRefPubMed
41.
van de Vijver MJ, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalesio O, Nusse R (1988) Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 319:1239–1245CrossRefPubMed
42.
Latta EK, Tjan S, Parkes RK, O’Malley FP (2002) The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast. Mod Pathol 15:1318–1325CrossRefPubMed
43.
Soomro S, Shousha S, Taylor P, Shepard HM, Feldmann M (1991) c-erbB-2 expression in different histological types of invasive breast carcinoma. J Clin Pathol 44:211–214CrossRefPubMed
44.
Somerville JE, Clarke LA, Biggart JD (1992) c-erbB-2 overexpression and histological type of in situ and invasive breast carcinoma. J Clin Pathol 45:16–20CrossRefPubMed
45.
Allred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ, Gilchrist KW, Osborne CK, Tormey DC, McGuire WL (1992) Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 23:974–979CrossRefPubMed
46.
Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403–410CrossRefPubMed
47.
WHO (2003) Tumors of the breast. In: Tavassoli FA, Devilee P (eds) World Health Organisation classification of tumors: pathology and genetics of tumours of the breast and female genital organs. IARC Press, Lyon, pp 9–112
48.
Sauter G, Simon R, Hillan K (2003) Tissue microarrays in drug discovery. Nat Rev Drug Discov 2:962–972CrossRefPubMed
49.
Al-Kuraya K, Schraml P, Torhorst J, Tapia C, Zaharieva B, Novotny H et al (2004) Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res 64:8534–8540CrossRefPubMed
50.
Kuerer HM, Albarracin CT, Yang WT, Cardiff RD, Brewster AM, Symmans WF et al (2009) Ductal carcinoma in situ: state of the science and roadmap to advance the field. J Clin Oncol 27:279–288CrossRefPubMed
51.
Glockner S, Lehmann U, Wilke N, Kleeberger W, Langer F, Kreipe H (2001) Amplification of growth regulatory genes in intraductal breast cancer is associated with higher nuclear grade but not with the progression to invasiveness. Lab Investig 81:565–571PubMed
52.
Park K, Han S, Kim HJ, Kim J, Shin E (2006) HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry. Histopathology 48:702–707CrossRefPubMed
53.
Done SJ, Arneson NC, Ozcelik H, Redston M, Andrulis IL (1998) p53 mutations in mammary ductal carcinoma in situ but not in epithelial hyperplasias. Cancer Res 58:785–789PubMed
54.
van der Groep P, van Diest PJ, Menko F, Bart J, de Vries E, van der Wall E (2009) Molecular profile of ductal carcinoma in situ of the breast in BRCA1 and BRCA2 germline mutation carriers. J Clin Pathol 62:926–930CrossRefPubMed
55.
Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA (2002) Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 62:1676–1681PubMed
56.
Dietrich D, Schuster M, Lesche R, Haedicke W, Kristiansen G (2007) Multiplexed methylation analysis—a new technology to analyse the methylation pattern of laser microdissected cells of normal breast tissue, DCIS and invasive ductal carcinoma of the breast. Verh Dtsch Ges Pathol 91:197–207PubMed
57.
Von Hoff DD, McGill JR, Forseth BJ, Davidson KK, Bradley TP, Van Devanter DR, Wahl GM (1992) Elimination of extrachromosomally amplified MYC genes from human tumor cells reduces their tumorigenicity. Proc Natl Acad Sci USA 89:8165–8169CrossRef
58.
Sontag L, Axelrod DE (2005) Evaluation of pathways for progression of heterogeneous breast tumors. J Theor Biol 232:179–189CrossRefPubMed
59.
Singletary SE (2002) A working model for the time sequence of genetic changes in breast tumorigenesis. J Am Coll Surg 194:202–216CrossRefPubMed
60.
Holst F, Stahl PR, Hellwinkel O, Dancau A, Krohn A, Wuth L et al (2008) Reply to “ESR1 gene amplification in breast cancer: a common phenomenon?”. Nat Genet 40:810–812CrossRef
Metadata
Title
Gene amplification in ductal carcinoma in situ of the breast
Authors
L. Burkhardt
T. J. Grob
I. Hermann
E. Burandt
M. Choschzick
F. Jänicke
V. Müller
C. Bokemeyer
R. Simon
G. Sauter
W. Wilczak
A. Lebeau
Publication date
01-10-2010
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-009-0675-8

Other articles of this Issue 3/2010

Breast Cancer Research and Treatment 3/2010 Go to the issue

Epidemiology

Adipocytokine resistin and breast cancer risk

Clinical trial

Bone mineral density loss during adjuvant chemotherapy in pre-menopausal women with early breast cancer: is it dependent on oestrogen deficiency?

Clinical trial

Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients

Preclinical study

Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer

Preclinical study

Transcriptional modulation of BCRP gene to reverse multidrug resistance by toremifene in breast adenocarcinoma cells

Preclinical study

Inhibition of mammary tumor growth by estrogens: is there a specific role for estrogen receptors alpha and beta?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits